Status:

TERMINATED

A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Lead Sponsor:

Bayer

Conditions:

Uterine Fibroids

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

The primary objective of this study is to describe the efficacy of vilaprisan in subjects with uterine fibroids compared to ulipristal. The secondary objective of this study is to evaluate the effica...

Eligibility Criteria

Inclusion

  • Women, 18 years or older at the time of Visit 1
  • Diagnosis of uterine fibroid(s) documented by ultrasound at screening with at least 1 fibroid with largest diameter more than 30 mm and less than 120 mm
  • Heavy menstrual bleeding (HMB) \>80.00 mL documented by menstrual pictogram (MP) in a bleeding episode period during the screening period
  • Use of an acceptable non-hormonal method of contraception
  • An endometrial biopsy performed during the screening period, without significant histological disorder such as endometrial hyperplasia (including simple hyperplasia) or other significant endometrial pathology

Exclusion

  • Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before start of treatment)
  • Hypersensitivity to any ingredient of the study drugs
  • Hemoglobin values ≤6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values ≤10.9 g/dL will be recommended to use iron supplementation)
  • Any diseases, conditions, or medications that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug including
  • Abuse of alcohol, drugs, or medicines (eg: laxatives)
  • Undiagnosed abnormal genital bleeding
  • Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results

Key Trial Info

Start Date :

July 31 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 25 2021

Estimated Enrollment :

766 Patients enrolled

Trial Details

Trial ID

NCT03240523

Start Date

July 31 2017

End Date

October 25 2021

Last Update

October 18 2024

Active Locations (139)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 35 (139 locations)

1

Paratus Clinical Pty Ltd

Blacktown, New South Wales, Australia, 2148

2

Paratus Clinical Wyong Complex

Kanwal, New South Wales, Australia, 2259

3

Women's Health and Research Institute of Australia-WHRIA

Sydney, New South Wales, Australia, 2000

4

Greenslopes Private Hospital

Greenslopes, Queensland, Australia, 4120